2 results
Approved WMOCompleted
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…
Approved WMORecruiting
By using advanced respiratory monitoring, we will aim to gain more understanding about the physiological effects and potential benefits of FCV in comparison to PCV in patients with moderate to severe ARDS. We hypothesize that FCV results in a lower…